Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

PURPOSE: To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in EGFR. PATIENTS AND METHODS: Patients with resectable stage I and II non-small cell lung cancer (NSCLC) enriched for the likelihood of EGFR mutation (≤ 15 pack year ci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rizvi, Naiyer A., Pao, William, Chaft, Jamie E., Ladanyi, Marc, Miller, Vincent A., Krug, Lee M., Azzoli, Christopher G., Bains, Manjit, Downey, Robert, Flores, Raja, Park, Bernard, Rusch, Valerie, Zakowski, Maureen, Heelan, Robert T., Shen, Ronglai, Kris, Mark G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3261615/
https://ncbi.nlm.nih.gov/pubmed/21558399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados